CompletedPhase 4

Evaluation of Myocardial Reperfusion After Primary PCI in Patients With High Platelet Reactivity Treated by Cangrelor or Not

France128 participantsStarted 2021-06-08

Plain-language summary

This study aims to evaluate the impact on myocardial reperfusion and residual thrombotic burden of adding Cangrelor -a potent and immediate P2Y12 inhibitor- to ticagrelor in primary PCI patients with high on ticagrelor platelet reactivity compared to standard of care with ticagrelor alone.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * patient admitted for STEMI within 24 hours from symptom onset * pretreated with ticagrelor, aspirin and enoxaparin (according local protocol) * successfully treated by primary PCI of a native coronary culprit lesion * anatomy accessible to optical coherence tomography (OCT or OFDI) Exclusion Criteria: * cardiogenic shock * stent restenosis or thrombosis * use of glycoprotein IIb/IIIa inhibitors before or during PCI * known coagulation disease * high bleeding risk (thrombocytopenia \<100,000/dL, surgery \<30 days, active bleeding) * uncontrolled arterial hypertension (\>180/110 mmHg) * history of stroke (ischemic or hemorrhagic) or transient ischemic attack * known severe renal insufficiency (eGFR \<30 ml/min) * oral anticoagulation

What they're measuring

Grade of myocardial blush

Timeframe: during procedure

Trial details

NCT IDNCT04927949

SponsorUniversity Hospital, Caen

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-03-31

View on ClinicalTrials.gov More ST-elevation Myocardial Infarction trials